Sight Sciences, Inc. Common Stock Morgan Stanley 24th Annual Global Healthcare Conference

Sure. Thanks. Good to be here.

Sight Sciences, we're an ophthalmic medical device company in growth stage. We are focused on two of the major problems in eye care, glaucoma and dry eye disease. Glaucoma is the world's leading cause of irreversible blindness, and dry eye disease is one of the top reasons for a visit to an eye care provider, for a patient to visit an eye care provider. We're an interventional company, so we believe strongly that patient care needs to move out of the hands of the patient and into the hands of the eye care provider.

So we've developed over many years, two compelling, clinically proven, and now commercial stage and growing interventional technologies, OMNI in the micro-invasive glaucoma surgery space, and TearCare in the interventional dry eye space. Excited both businesses are growing. MIGS is back in growth and OMNI is back in growth mode, and TearCare on the dry eye side is also growing very nicely commercially as we're working to secure additional payer wins and market access in parallel.

Yeah, I think we're quite different today. Several years ago, we were primarily an OMNI MIGS company.

That product was in growth mode. TearCare, lots of work was getting done, great work getting done in the field with our team, development work, perfecting the technology, running multiple RCTs to prove it out, and to ultimately secure reimbursement. But the headline of the company, the headline story was OMNI and MIGS. For several years, there was a challenge with Medicare around what they would cover, what they wouldn't cover, and it kind of took us sideways as a public company with a single product.

But now fast-forward 12 months, and as I mentioned in my opening remarks, we are very excited to be back in growth mode with both businesses. OMNI is back in growth. The MIGS market is back in growth. Our team is as laser-focused on MIGS and on making OMNI a standard of care as the leading implant-free MIGS technology, so that's very different.

I'd say on the interventional dry eye side of our business, it's night and day. If you go back a year, we didn't have any market access.

Right A year ago, it was less than a year ago, we secured our first two successful payer coverage in First Coast and Novitas.

With that reimbursement, we have been hiring great people who are locked in and focused on the opportunity and training eye care providers on the TearCare procedure, and we're growing a very nice business.

We've been almost doubling every quarter since we got reimbursement.

Yeah. Growing that business is very encouraging, and in parallel again, we're working on both driving more depth of coverage in the First Coast and Novitas regions, the 13 states that are covered by those two MACs, as well as broadening access beyond First Coast and Novitas.